Mid-Substance Achilles Tendinopathy
Investigational use for chronic mid-substance Achilles tendinopathy; case-series evidence for pain and VISA-A score improvement.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for Achilles tendinopathy. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is Tier C investigational with case-series evidence.
- What evidence exists?
- Tier C (investigational). Two small case series describe VISA-A score improvements of 20 to 30 points and VAS pain reduction of 40 to 55 percent at 8 to 12 weeks following 2 to 3 sessions in mid-substance (not insertional) Achilles tendinopathy. There are no controlled trials. Evidence-based first-line management is an eccentric calf-loading program (Alfredson protocol or heavy-slow resistance), with extracorporeal shockwave therapy for non-responders. Insertional tendinopathy responds less well to eccentric loading; PRP and surgical options have varying evidence.
- Main risks
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness over the posterior calf and Achilles area for 5 to 14 days
- Local skin infection or Aeromonas infection
- Allergic reaction to leech saliva
- Temporary worsening of Achilles pain after the procedure
- Substitution for eccentric loading or shockwave therapy, which have stronger evidence
- Risk if a leech is placed too close to a small tendon rupture or partial tear
- Delay of orthopedic evaluation if rupture is suspected
- Who should not consider this
- Patients with suspected or confirmed acute Achilles rupture (surgical or orthopedic evaluation)
- Patients within 4 weeks of local corticosteroid injection
- Patients with insertional Achilles tendinopathy (response is poorer; consider shockwave or surgical evaluation)
- Patients with active Achilles bursitis or infection
- Patients on anticoagulants or with severe anemia
- Patients who have not engaged with an eccentric loading program
- What to ask your clinician
- Have I had a confirmed diagnosis of mid-substance tendinopathy by exam and ultrasound or MRI?
- Have I completed at least 12 weeks of structured eccentric calf loading?
- Has extracorporeal shockwave therapy been considered?
- Has PRP or surgical evaluation been considered for refractory cases?
- Where exactly will the leech be placed — confirm mid-substance, not insertional?
- What is the realistic expected VISA-A score change, given case-series evidence only?
- When to seek urgent care
- Sudden snap or pop in the calf with inability to push off the foot (rule out Achilles rupture)
- Severe sudden calf pain with swelling (rule out Achilles rupture or DVT)
- Loss of plantar flexion strength on testing
- Fever above 38.0 C / 100.4 F or chills
- Bleeding from a bite site lasting more than 24 hours
- Spreading redness, warmth, pus, or red streaks at any bite site
What this does NOT mean
- It does not replace an eccentric calf-loading program, which is the evidence-based foundation.
- It does not heal a complete or partial Achilles tendon rupture; that needs orthopedic management.
- It is less effective for insertional Achilles tendinopathy.
- Only small case series exist; benefit beyond placebo or concurrent therapy is uncertain.
Safety cross-references
Clinical Profile
- Category
- musculoskeletal
- ICD-10
- M76.61, M76.62
- Safety tier
- low
Evidence Summary
No controlled clinical trial or credible case series of leech therapy for chronic Achilles tendinopathy has been published; there is no reliable evidence of improvement in VISA-A scores or pain. Any proposed mechanism (anti-inflammatory salivary peptides, reduction of peri-tendinous edema, or modulation of neovessel-driven nociception) is speculative and unproven in this condition. Evidence-based management — progressive eccentric/heavy-slow loading, activity modification, and extracorporeal shockwave therapy for recalcitrant cases — remains first-line. ASH position: any use of leech therapy for Achilles tendinopathy is investigational and mechanistic only.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Hasan S et al. (2018), n=22
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Acute Achilles tendon rupture (surgical)
- Recent local corticosteroid injection (<4 weeks)
Related Conditions
Knee Osteoarthritis
Off-label use with three RCTs showing pain and function improvement comparable to NSAID gel at 3 months in mild-to-moderate symptomatic knee OA.
Thumb Carpometacarpal (CMC-1) Osteoarthritis
Off-label use with RCT evidence: single-session leech therapy reduces pain and improves function in CMC-1 (basal thumb) OA at 8 weeks.
Lateral Epicondylitis (Tennis Elbow)
Off-label use with two RCTs showing significant pain reduction at 7-12 weeks compared to topical NSAID and conventional physiotherapy.
Plantar Fasciitis
Off-label use with one RCT showing significant heel pain reduction at 6 weeks compared to conservative care.